Italia markets closed

JNJ Oct 2024 140.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,8000-0,5000 (-15,15%)
Alla chiusura: 02:37PM EDT
Schermo intero
Chiusura precedente3,3000
Aperto3,1500
Denaro2,6400
Domanda2,9000
Prezzo d'esercizio140,00
Scadenza2024-10-18
Min-Max giorno2,6500 - 3,2300
Contratto - Min-MaxN/D
Volume26
Open Interest609
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA